Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II XanADu trial results, only to rebound in October 2019 almost to per-XanADu levels after preliminary results from another clinical trial XanaHES were reported. XanaHES was designed as a Phase I safety trial to test high doses of Xanamem, but a smart trial design (exploratory cognitive endpoints included) and well-timed initiation led to the right r
15 Oct 2019
Actinogen Medical - Well-timed XanaHES study saves the day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Actinogen Medical - Well-timed XanaHES study saves the day
Actinogen Medical Limited (ACW:ASX) | 0 0 -9.4% | Mkt Cap: 35.9m
- Published:
15 Oct 2019 -
Author:
Dr Jonas Peciulis -
Pages:
8
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II XanADu trial results, only to rebound in October 2019 almost to per-XanADu levels after preliminary results from another clinical trial XanaHES were reported. XanaHES was designed as a Phase I safety trial to test high doses of Xanamem, but a smart trial design (exploratory cognitive endpoints included) and well-timed initiation led to the right r